University of Oxford Starts Phase I Clinical Trial of Novel HIV Vaccine
The University of Oxford has commenced a Phase I clinical trial of a novel HIV vaccine candidate with vaccinations underway
Read more
HIV
CABENUVA approved by the FDA as first long-acting HIV regimen
The U.S FDA has given the green light to Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for
Read more
ViiV Healthcare’s two-drug combo non-inferior to 3-drug HIV regimen
ViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read more
Enzolytics and BioClonetics intent to merge sends stock parabolic
Enzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read more